tiprankstipranks
The Fly

Enliven initiated with a Buy at Mizuho

Enliven initiated with a Buy at Mizuho

Mizuho initiated coverage of Enliven Therapeutics with a Buy rating and $34 price target. The company has validated biology, differentiated chemistry and disciplined trial design to bring new life to standards of care, the analyst telsl investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com